Because of the clinical relevance of the alterations in the VEGF signaling, inhibitors of this pathway, such as tyrosine kinase receptors, are currently being investigated in clinical trials [7,8,9] in those patients diagnosed with osteosarcoma who have previously progressed to chemotherapy [10,11] and as maintenance treatment after complete remission [12]. This evidence concerns the gene VEGFA and osteosarcoma.